38 results on '"Howlett, Jonathan G."'
Search Results
2. Integration of longitudinal and circumferential strain predicts volumetric change across the cardiac cycle and differentiates patients along the heart failure continuum
3. Prevalence, incidence and clinical outcomes of epicardial coronary artery disease among transthyretin amyloidosis cardiomyopathy patients
4. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
5. Abstract 14430: The Corcare Heart Function Optimization Protocol: A Structured Quality Improvement Intervention to Improve Goal Directed Targets for Patients With Reduced Ejection Fraction
6. The Need for Fiber Addition in Symptomatic Heart Failure (FEAST-HF): A Randomized Controlled Pilot Trial
7. Right Ventricular Systolic Pressure Trajectory as a Predictor of Hospitalization and Mortality in Patients With Chronic Heart Failure
8. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
9. Un(b)locking therapeutic options: potential for calcium channel blockers in heart failure with non‐reduced left ventricular ejection fraction
10. Feasibility of Sildenafil for the Prevention of Right Heart Failure Following Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial
11. What Difference Does a Day Make?
12. Feasibility of Sildenafil for the Prevention of Right Heart Failure After Continuous-Flow Left Ventricular Assist Device Implantation: The REVAD Trial
13. Predicting Heart Failure With Reduced or Preserved Ejection Fraction From Health Records
14. NOVEL HFREF ALGORITHM DEMONSTRATES A SAFE AND EFFECTIVE STRATEGY FOR RAPID GDMT TITRATION
15. Is it time to relitigate SGLT2 Inhibitor dose for heart failure?
16. Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure
17. Hematopoietic Cell Transplantation for Systemic Sclerosis—A Review
18. Clinical Phenotypes of Heart Failure across the spectrum of Ejection Fraction: A Cluster Analysis
19. The International Endomyocardial Biopsy Position Paper: A Basis for Integration Into Modern Clinical Practice
20. Amyloidosis Tissue Confirmation for Tafamidis Eligibility Using Transverse Carpal Ligament and Tenosynovium Biopsy
21. Can Machines Find the Sweet Spot in End-Stage Heart Failure?
22. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
23. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction:insights from DAPA-HF
24. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial
25. Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
26. Prevalence, Incidence and Clinical Outcomes of Epicardial Coronary Artery Disease Among Transthyretin Amyloidosis Cardiomyopathy Patients
27. TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY DISEASE STAGING SYSTEMS FOR PATIENTS TREATED WITH TAFAMIDIS THERAPY
28. MAGNITUDE AND TIMING OF CHANGE IN MONITORING PARAMETERS FOR TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY PATIENTS TREATED AND UNTREATED WITH TAFAMIDIS
29. BASELINE PREDICTORS OF MAJOR ADVERSE EVENTS FOR TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY PATIENTS TREATED AND UNTREATED WITH DISEASE-MODIFYING THERAPY
30. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure
31. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
32. Abstract 12120: Cost-Effectiveness of Earlier Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With a History of Heart Failure
33. Abstract 9464: Left Ventricular Ejection Fraction Trajectory Predicts Outcomes in Patients With Heart Failure and Mildly Reduced Ejection Fraction
34. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF.
35. Cardiac remodelling predicts outcome in patients with chronic heart failure.
36. Factors Influencing Clinical Initiation of Tafamidis Therapy for Transthyretin Amyloidosis Cardiomyopathy: A Canadian Referral Center Experience
37. Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center Experience.
38. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.